Detection of survivin, carcinoembryonic antigen and ErbB2 level in oral squamous cell carcinoma patients.
BACKGROUND
The aim of this study was to detect the survivin, carcinoembryonic antigen (CEA) and ErbB2 in the saliva, serum and local tumor-exfoliated cells of oral squamous cell carcinoma (OSCC) patients, for providing reliable tumor markers for the early detection of oral malignant cancer.


METHODS
The saliva, serum, and local tumor-exfoliated cell samples of 26 OSCC patients without chemotherapy and 10 non-cancer patients were collected in Department of Oral and Maxillofacial Surgery, School of Stomatology, Peking University. The contents of survivin, CEA and ErbB2 using were detected usingenzyme-linked immunosorbent assay.


RESULTS
The survivin and CEA levels in saliva and local tumor-exfoliated cells of OSCC patients were significantly higher than those in the non-cancer patients (P < 0.05), but there was no significant difference in the content of the above factors in the serum sample between two groups. There was no significant difference in the ErbB2 content in the saliva, serum or local tumor-exfoliated cells between two groups.


CONCLUSIONS
Survivin and CEA levels are significantly increased in the saliva and local tumor-exfoliated cells in OSCC patients, and they can be used as reliable markers for the early detection of oral malignant cancer.
Department of Periodontics {&} Oral Medicine, School of Stomatology, Capital Medical University, Beijing, China.
Shu-Xia
SX
Li
Department of Orthodontics, Faculty of Dentistry, Hong Kong University, HK, China.
Yan-Qi
YQ
Yang
Department of Orthodontics, Faculty of Dentistry, Hong Kong University, HK, China.
Li-Jian
LJ
Jin
Department of Maxillofacial Surgery, School of Stomatology, Peking University, Beijing, China.
Zhi-Gang
ZG
Cai
Department of Periodontics {&} Oral Medicine, School of Stomatology, Capital Medical University, Beijing, China.
Zheng
Z
Sun
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000032:analysis* / Q000097:blood / Q000378:metabolism; D002272:Carcinoembryonic Antigen / Q000032:analysis* / Q000097:blood / Q000378:metabolism; D002294:Carcinoma, Squamous Cell / Q000097:blood / Q000737:chemistry* / Q000378:metabolism; D005260:Female; D006258:Head and Neck Neoplasms / Q000097:blood / Q000737:chemistry* / Q000378:metabolism; D006801:Humans; D051034:Inhibitor of Apoptosis Proteins / Q000032:analysis* / Q000097:blood / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D009062:Mouth Neoplasms / Q000097:blood / Q000737:chemistry* / Q000378:metabolism / Q000473:pathology; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis* / Q000097:blood / Q000378:metabolism; D012463:Saliva / Q000737:chemistry / Q000378:metabolism; D000077195:Squamous Cell Carcinoma of Head and Neck; D000077022:Survivin
D014408:Biomarkers, Tumor; D002272:Carcinoembryonic Antigen; D051034:Inhibitor of Apoptosis Proteins; D018719:Erb-b2 Receptor Tyrosine Kinases; D000077022:Survivin; C107489:BIRC5 protein, human; C508053:ERBB2 protein, human
CEA; ErbB2; Oral squamous cell carcinoma; detection; survivin